<DOC>
	<DOCNO>NCT01162096</DOCNO>
	<brief_summary>Many patient hematological malignancy ( leukemia , lymphoma , multiple myeloma ) undergo hematopoietic stem cell transplantation ( HSCT ) well match donor . HSCT partially match family donor ( haploidentical HSCT ) option patient associated poor outcome . This study design test whether use exact amount donor 's lymphocyte ( white cell ) divide transplant process 2 step , would increase overall survival decreasing complication . The therapy reduce intensity target , limited , patient age 65 previous transplant .</brief_summary>
	<brief_title>Reduced Intensity Haploidentical Transplant Hematological Malignancies</brief_title>
	<detailed_description>Haploidentical hematopoietic stem cell transplant life save therapy patient without well match donor . This type therapy associate poor outcome past due complication infection . The Jefferson 2 Step approach design allow infusion exact dose tolerized lymphocyte haploidentical transplant order allow immune reconstitution post transplant avoid infectious complication still acceptable rate GVHD . In approach , old patient patient transplant previously high-risk hematological malignancy undergo chemotherapy fludarabine cytarabine thiotepa . The patient receive exact dose donor ' lymphocyte . The phase I portion study determine optimal dose lymphocyte . Two day receive donor lymphocyte , patient receive 2 daily dos cyclophosphamide . The purpose cyclophosphamide in-vivo tolerization lymphocyte . One day receive cyclophosphamide , patient receive stem cell donor . Tacrolimus mycophenolate mofetil use GVHD prophylaxis .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Any patient hematologic oncologic diagnosis allogeneic HSCT think beneficial , frontline therapy already apply . 2 . Patients must relate donor two allele mismatch HLAA ; B ; C ; DR locus . 3 . Patients sibling donor one antigen mismatch due recombination enrol protocol . 4 . Patients must adequate organ function : 1 . LVEF &gt; 45 % 2 . DLCO &gt; 45 % predict correct hemoglobin 3 . Adequate liver function define serum bilirubin &lt; 1.8 , AST ALT &lt; 2.5X upper limit normal 4 . Serum creatinine &lt; 2.0 mg/dl creatinine clearance &gt; 40 ml/min 5 . Performance status &gt; 70 % ( Karnofsky ) 6 . Patients must willing use contraception childbearing potential 7 . Able give inform consent 1 . Performance status &lt; 70 % ( Karnofsky ) 2 . HIV positive 3 . Active involvement central nervous system malignancy 4 . Psychiatric disorder would preclude patient sign informed consent 5 . Pregnancy 6 . Patients life expectancy &lt; 6 month reason underlie hematologic/oncologic disorder complication . 7 . Patients receive alemtuzumab within 8 week transplant admission , recently receive horse rabbit antithymocyte globulin ATG level &gt; 2 Âµgm/ml . 8 . Patients receive cyclophosphamide 9 . Patients evidence another malignancy , exclusive skin cancer require local treatment , enrol protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Reduced Intensity Haploidentical Transplant</keyword>
</DOC>